A differentiated effector T cell repertoire defines a functionally high-risk group of smoldering myeloma patients ...
Study design, patient eligibility and treatment This was a phase 1, first-in-human, open-label, nonrandomized, dose-escalation ...
Lebrun-Frenay C, Rollot F, Mondot L, Zephir H, Louapre C, Le Page E, et al. ...
According to the CDC, more than 42 million individuals in America are now impacted by human ...
From a general health standpoint, citicoline has been found to help maintain cognitive function during ...
We start with a case report, because it illustrates well the current challenges and possibilities ...
Giebel S, Labopin M, Socie G, Beelen D, Browne P, Volin L, et al. Improving ...
What rheumatology can learn from oncology: a patient’s perspective ...
Minhas AMK, Marcus R, Virani SS, Shapiro MD, Mentz RJ, Echeverria LE, et al. Worldwide ...
Friday, January 23, 2026 WASHINGTON — Jan. 23, 2026 — The National Institutes of Health ...